Boundless Bio Inc. (BOLD), a clinical-stage oncology company based in San Diego, has announced the appointment of Robert Doebele as their new Chief Medical Officer. The company is progressing with its BBI-355 Phase 1/2 POTENTIATE trial and is preparing to select a development candidate for its Kinesin program.
Dr. Doebele comes with substantial expertise in the field of precision oncology, having co-founded Rain Oncology, Inc. where he served as Chief Scientific and Medical Officer.
Currently, BOLD's stock is trading at $2.31, reflecting an increase of 0.87% or $0.02 on the Nasdaq.
